Pfizer Inc. (PFE)

Statement of Cash Flows
Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Pfizer Inc., Consolidated Statement of Cash Flows (quarterly data)

USD $ in millions

	3 months ended	Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jul 1, 2018		Apr 1, 2018		Dec 31, 2017		Oct 1, 2017		Jul 2, 2017		Apr 2, 2017		Dec 31, 2016		Oct 2, 2016		Jul 3, 2016		Apr 3, 2016		Dec 31, 2015		Sep 27, 2015		Jun 28, 2015		Mar 29, 2015		Dec 31, 2014		Sep 28, 2014		Jun 29, 2014		Mar 30, 2014
	Net income before allocation to noncontrolling interests
	Depreciation and amortization
	Asset write-offs and impairments
	Adjustments to loss on sale of HIS net assets
	TCJA impact
	Foreign currency loss related to Venezuela
	Adjustment to (gain) loss on disposal of discontinued operations
	Deferred taxes from continuing operations
	Deferred taxes from discontinued operations
	Share-based compensation expense
	Benefit plan contributions in excess of income and expense
	Other adjustments, net
	Other changes in assets and liabilities, net of acquisitions and divestitures
	Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities
	Net cash provided by operating activities
	Purchases of property, plant and equipment
	Purchases of short-term investments
	Proceeds from redemptions/sales of short-term investments
	Net (purchases of) proceeds from redemptions/sales of short-term investments with original maturities of three months or less
	Purchases of long-term investments
	Proceeds from redemptions/sales of long-term investments
	Acquisitions of businesses, net of cash acquired
	Acquisitions of intangible assets
	Other investing activities, net
	Net cash (used in) provided by investing activities
	Proceeds from short-term borrowings
	Principal payments on short-term borrowings
	Net proceeds from (payments on) short-term borrowings with original maturities of three months or less
	Proceeds from issuance of long-term debt
	Principal payments on long-term debt
	Purchases of common stock
	Cash dividends paid
	Proceeds from exercise of stock options
	Other financing activities, net
	Net cash used in financing activities
	Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
	Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents

Item	Description	The company
Net cash provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Pfizer Inc.’s net cash provided by operating activities declined from Q4 2018 to Q1 2019 but then slightly increased from Q1 2019 to Q2 2019.
Net cash (used in) provided by investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Pfizer Inc.’s net cash (used in) provided by investing activities increased from Q4 2018 to Q1 2019 but then declined significantly from Q1 2019 to Q2 2019.
Net cash used in financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Pfizer Inc.’s net cash used in financing activities declined from Q4 2018 to Q1 2019 but then increased from Q1 2019 to Q2 2019 exceeding Q4 2018 level.

	Pfizer Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Pfizer Inc. (PFE)

Statement of Cash FlowsQuarterly Data

Statement of Cash Flows
Quarterly Data